US Pharma MarketingGilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population
Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population is a pharma and life sciences industry update from FiercePharma. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint, showing that after 52 weeks it can normalize a key marker of disease progression for those with the liver disorder primary biliary cholangitis.
Source: FiercePharma